colchicine vs fenofibrate
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of colchicine and fenofibrate. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
7.4 Colchicine Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.
Colcrys, Mitigare
TriCor, Antara
Colchicine is a medicine used to prevent or treat gout flares and Familial Mediterranean Fever (FMF). It works by reducing inflammation and pain.
Fenofibrate is a medicine that helps lower bad cholesterol and fats (triglycerides) in your blood, while raising good cholesterol.
Colchicine is used to prevent and treat gout flares in adults. Gout flares cause sudden, severe pain, redness, and swelling in your joints. Colchicine is also used to treat Familial Mediterranean Fever (FMF) in adults and children ages 4 and older. FMF causes recurring fevers and pain in the abdomen, chest, or joints.
This medicine is used with a diet to treat high cholesterol and high levels of triglycerides (fats) in the blood. It helps adults who have primary hypercholesterolemia or mixed dyslipidemia. It can also treat adults with severe hypertriglyceridemia. However, fenofibrate has not been proven to prevent heart disease in people with type 2 diabetes.
Colchicine reduces inflammation in the body. It does this by blocking certain processes that cause swelling and pain. This helps to relieve gout flares and manage FMF symptoms.
Fenofibrate is a type of drug called a PPAR alpha agonist. It works by activating a protein in your body that helps break down fats and cholesterol. This leads to lower levels of bad cholesterol and triglycerides, and higher levels of good cholesterol.
- • Diarrhea
- • Abdominal pain
- • Nausea
- • Vomiting
- • Abnormal liver function tests
- • Increased ALT (a liver enzyme)
- • Increased AST (a liver enzyme)
- • Increased CPK (a muscle enzyme)
- • Runny nose
- Diarrhoea 2,660
- Nausea 1,940
- Fatigue 1,747
- Dyspnoea 1,467
- Acute Kidney Injury 1,436
- Nausea 2,912
- Fatigue 2,840
- Diarrhoea 2,681
- Dyspnoea 2,099
- Headache 2,058
Taking too much colchicine can be fatal in both adults and children. Keep this medicine out of the reach of children. Colchicine can also cause serious blood problems and muscle weakness. Certain medicines can interact with colchicine and cause life-threatening problems. Talk to your doctor about all the medicines you take.
Fenofibrate can cause liver problems. Your doctor should check your liver function with blood tests before you start taking it and regularly while you are taking it. Stop taking fenofibrate and tell your doctor right away if you have signs of liver problems, such as yellowing of your skin or eyes, dark urine, or stomach pain. Fenofibrate can also cause muscle pain or weakness, especially if you are also taking a statin medicine. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness.
Tell your doctor if you are pregnant or plan to become pregnant. Colchicine may harm your unborn baby. It is not known if colchicine passes into breast milk. Talk to your doctor about the risks and benefits of taking colchicine while breastfeeding.
It is not known if fenofibrate will harm an unborn baby. You should only use fenofibrate during pregnancy if your doctor decides that the benefit outweighs the risk. You should not breastfeed while taking fenofibrate.
Also Compare, Nearby Drugs
Compare fenofibrate with
How to Read This colchicine vs fenofibrate Comparison
colchicine is classified in the Anti-Gout Agent drug class, while fenofibrate sits within the Fibrate class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, colchicine has 9,250 submissions while fenofibrate has 12,590. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to combining these drugs can lead to a higher risk of severe muscle pain and muscle breakdown.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for colchicine or fenofibrate.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.